title: Unilateral branch retinal arterial occlusion following administration of bevacizumab for branch retinal vein occlusion.
abstract: Intravitreal bevacizumab has been adopted as a well-established treatment modality for the treatment of macular edema associated with branch retinal vein occlusion. It is considered a safe and efficacious option for improving visual acuity. We present an interesting case of unilateral superotemporal branch retinal vein occlusion in a 55-year-old man who received two doses of intravitreal bevacizumab one month apart. Laboratory tests including complete hypercoagulability and thrombotic work-up were completed but the patient successively developed branch retinal artery occlusion. We reviewed cases in literature and combined possible etiologies. We report a previously unpublished case of retinal artery occlusion following the use of intravitreal bevacizumab. Several studies have shown evidence of systemic thromboembolic events after the use of intravenous and systemic bevacizumab; however, to the best of our knowledge, no case has been reported of retinal artery occlusion immediately after administration of intravitreal bevacizumab.
authors.affiliation: Advanced Eye Centre, PGIMER, Chandigarh, Punjab, India, mailsavleen@gmail.com.
authors.forename: Savleen
authors.initials: S
authors.lastname: Kaur
authors.forename: Nishant
authors.initials: N
authors.lastname: Sachdev
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D015356:Retinal Artery Occlusion / Q000139:chemically induced*; D012170:Retinal Vein Occlusion / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab